ClinicalTrials.gg

Program

Levetiracetam

Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.

Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.

Furthest: phase 4, since Sep 8, 200572 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB570 open or runningphase 4since Sep 8, 2005Mar 3, 2005none ahead
Hikma Pharmaceuticals40 open or runningno phasesince Jan 15, 2009Jan 15, 2009none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Feb 20, 2009Feb 20, 2009none ahead
AgeneBio20 open or runningphase 3since Mar 28, 2018Mar 28, 2018none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since May 26, 2010May 26, 2010none ahead
Ache Laboratorios Farmaceuticos10 open or runningphase 3since Jul 6, 2011Jul 6, 2011none ahead
Desitin Arzneimittel10 open or runningphase 1since Dec 1, 2025Dec 1, 2025none ahead
Novartis10 open or runningphase 1since Jul 24, 2009Jul 24, 2009none ahead

Also a collaborator on its studies: pra-health-sciences and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Sep 8, 2005.

  1. Jul 6, 2011Ache Laboratorios Farmaceuticos's first study: phase 3 study in EpilepsyNew to Ache Laboratorios FarmaceuticosAche Laboratorios Farmaceuticos · NCT01392768 · 126 enrolled
  2. Jul 12, 2011Phase 1 study in Healthy VolunteersUCB · NCT01394224 · 25 enrolled · United Kingdom
  3. Jul 13, 2011Phase 3 study in EpilepsyUCB · NCT01398956 · 44 enrolled · Japan
  4. Jul 29, 2011Phase 2 study in EpilepsyUCB · NCT01407523 · 16 enrolled · Japan
  5. Dec 9, 20112 phase 4 studiesUCB · NCT01491113, NCT01498822
  6. Jan 5, 2012Phase 3 study in EpilepsyUCB · NCT01506882 · 71 enrolled · Japan
  7. Jun 11, 20122 phase 1 studies in Human VolunteersUCB · NCT01618903, NCT01618877
  8. Nov 7, 2012Phase 1 study in Healthy VolunteersUCB · NCT01725009 · 32 enrolled · Japan
  9. Sep 26, 2013Phase 3 study in EpilepsyUCB · NCT01954121 · 436 enrolled · China
  10. Nov 6, 2015Phase 1 study in Healthy VolunteersUCB · NCT02602860 · 13 enrolled · United States
  11. Nov 8, 2017Phase 3 study in SeizuresUCB · NCT03340064 · 38 enrolled · Japan
  12. Mar 28, 2018AgeneBio's first study: phase 3 study in Cognitive DysfunctionNew to AgeneBioAgeneBio · NCT03486938 · 164 enrolled · United States, Canada
  13. Aug 3, 2023Phase 2 study in Cognitive DysfunctionAgeneBio · NCT05986721 · United States
  14. Dec 1, 2025Desitin Arzneimittel's first study: phase 1 study in Pharmacokinetic AnalysisNew to Desitin ArzneimittelDesitin Arzneimittel · NCT07393022 · 20 enrolled · Canada

TargetBeta

“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule

Studies

The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07393022Pharmacokinetic Analysis · Canada1CompletedDesitin ArzneimittelJan 5, 202620
NCT05986721Cognitive Dysfunction · United States2WithdrawnAgeneBioJul 20280
NCT03486938Cognitive Dysfunction · United States, Canada3CompletedAgeneBioNov 2, 2022164
NCT03340064Seizures · Japan3CompletedUCBJun 1, 202138
NCT02602860Healthy Volunteers · United States1CompletedUCBSep 201713
NCT01954121Epilepsy · China3CompletedUCBSep 2015436
NCT01725009Healthy Volunteers · Japan1CompletedUCBDec 201232
NCT01618903Human Volunteers · China1CompletedUCBJul 201224
NCT01618877Human Volunteers · China1CompletedUCBJul 201224
NCT01506882Epilepsy · Japan3CompletedUCBOct 201371
NCT01498822Epilepsy · Korea, Republic of4CompletedUCBJul 2014353
NCT01491113Healthy Subjects · Japan4CompletedUCBNov 201230
NCT01407523Epilepsy · Japan2CompletedUCBFeb 201216
NCT01398956Epilepsy · Japan3CompletedUCBApr 201644
NCT01394224Healthy Volunteers · United Kingdom1CompletedUCBSep 201125
NCT01392768Epilepsy3CompletedAche Laboratorios FarmaceuticosJul 2015126
NCT01375374Epilepsies, Partial · Austria, Germany, Spain3TerminatedUCBMar 201311
NCT01292837Epilepsy · Japan3CompletedUCBJun 201313
NCT01229735Epilepsy · Korea, Republic of4CompletedUCBMay 2015343
NCT01228747Epilepsy · China, Japan3CompletedUCBApr 2014361
NCT01132352Healthy · United States1CompletedDr. Reddy's LaboratoriesOct 200324
NCT01131897Healthy · United States1CompletedDr. Reddy's LaboratoriesSep 200324
NCT01063764Epilepsy · Japan3CompletedUCBApr 201173
NCT00985348Healthy · United Kingdom1CompletedUCBOct 200926
NCT00961441Epilepsy · United States2CompletedUCBMar 201025
NCT00946751Seizures1CompletedNovartisMar 200420
NCT00859521Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200730
NCT00859430Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200722
NCT00849862Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200522
NCT00849485Healthy · Canada1CompletedTeva Pharmaceutical IndustriesNov 200522
NCT00826787Seizures · United States–CompletedHikma PharmaceuticalsAug 200529
NCT00827320Seizures · United States–CompletedHikma PharmaceuticalsJun 200726
NCT00826865Seizures · United States–CompletedHikma PharmaceuticalsAug 200527
NCT00826722Seizures · United States–CompletedHikma PharmaceuticalsJun 200730
NCT00631150Epilepsy4CompletedUCBJul 200435
NCT00630968Epilepsy4CompletedUCBFeb 20041,541
NCT00630630Epilepsy4CompletedUCBNov 20033
NCT00630357Epilepsy4CompletedUCBJul 200414
NCT00643500Epilepsies, Partial4CompletedUCBMay 2003342
NCT00615615Epilepsy3CompletedUCBMar 2003216
NCT00610454Epilepsy2CompletedUCBAug 200425
NCT00612859Anxiety Disorders2CompletedUCBJun 2004217
NCT00600509Epilepsy2CompletedUCBJul 2003216
NCT00545012Seizures2CompletedUCBMay 20034
NCT00544050Epilepsy2CompletedUCBMay 200313
NCT00535392Epilepsy · United States, Belgium, France and more2CompletedUCBFeb 201033
NCT00505934Epilepsy · United States, Belgium, France and more2CompletedUCBMar 201019
NCT00419393Epilepsy · United States, Mexico, Poland and more3CompletedUCBMar 2010190
NCT00419094Epilepsy · United States, Mexico, Poland and more3CompletedUCBSep 2009228
NCT00367432Epilepsy · Japan3CompletedUCBDec 2010398
NCT00368069Epilepsy · Brazil, Finland, India and more3CompletedUCBMay 2007158
NCT00291655Epilepsy · Belgium, Bulgaria, Finland and more3CompletedUCBApr 2008130
NCT00280696Epilepsies, Partial · Japan3CompletedUCBNov 2007352
NCT00245713Epilepsies, Partial4CompletedUCBNov 200440
NCT00175955Dyskinesia, Drug-Induced · Belgium, Bulgaria2CompletedUCBDec 200570
NCT00175903Epilepsy · Australia, Austria, Belgium and more3CompletedUCBOct 20071,701
NCT00175890Epilepsies, Partial · United States, Argentina, Belgium and more3CompletedUCBJan 2007116
NCT00160654Epilepsies, Partial · Hong Kong, Malaysia, Philippines and more4CompletedUCBDec 12, 2006251
NCT00160628Epilepsies, Partial3CompletedUCBOct 2004100
NCT00160615Epilepsies, Partial3CompletedUCBJan 17, 2007154

How it is read

Names in the registry

  • “Levetiracetam”, 52 entries
  • “Levetiracetam (Keppra)”, 4 entries
  • “levetiracetam”, 3 entries
  • “Levetiracetam 250 mg”, 3 entries
  • “Levetiracetam 500 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.